Bevacizumab therapy in patients with recurrent uterine neoplasms

Jason D. Wright, Matthew A. Powell, Janet S. Rader, David G. Mutch, Randall K. Gibb

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Background: Angiogenesis plays an important role in endometrial carcinogenesis. We reviewed our experience with the anti-VEGF monoclonal antibody bevacizumab for the treatment of recurrent uterine neoplasms. Patients and Methods: A retrospective analysis of women with recurrent uterine neoplasms treated with bevacizumab was performed. Results: A total of 11 patients were identified, 9 with epithelial endometrial carcinomas and 2 with leiomyosarcomas. All patients had multi-site disease and were heavily pretreated with a median of 3 prior chemotherapy regimens. All received bevacizumab combination therapy which was well-tolerated. Two patients had partial responses, 3 had stable disease, while 5 patients progressed. One subject was not assessable for response. The median progression-free interval was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit (PR or SD). Conclusion: Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma.

Original languageEnglish
Pages (from-to)3525-3528
Number of pages4
JournalAnticancer research
Issue number5 B
StatePublished - Sep 2007


  • Angiogenesis
  • Bevacizumab
  • Endometrial cancer
  • Uterine cancer


Dive into the research topics of 'Bevacizumab therapy in patients with recurrent uterine neoplasms'. Together they form a unique fingerprint.

Cite this